<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04993755</url>
  </required_header>
  <id_info>
    <org_study_id>TPN-101-C9-201</org_study_id>
    <nct_id>NCT04993755</nct_id>
  </id_info>
  <brief_title>A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD</brief_title>
  <official_title>A Phase 2a Study of TPN-101 in Patients With Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated With Hexanucleotide Repeat Expansion in the C9orf72 Gene (C9ORF72 ALS/FTD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Transposon Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Transposon Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a study to assess the the safety and tolerability of TPN-101 in patients&#xD;
      with Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) Associated with&#xD;
      Hexanucleotide Repeat Expansion in the C9orf72 gene (C9ORF72 ALS/FTD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a multi-center, randomized, double-blind, placebo-controlled parallel-group,&#xD;
      2-arm study with a long-term, open-label treatment phase in patients with C9ORF72 ALS and/or&#xD;
      FTD. This study includes a 6-week Screening Period, a 24-week Double-blind Treatment Period,&#xD;
      a 24-week Open-label Treatment Period, and a Follow-up Visit 4 weeks post-treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the safety and tolerability of TPN-101 in patients with C9ORF72 amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Incidence and severity of spontaneously reported treatment-emergent adverse events (TEAEs) associated with TPN-101 v. placebo administered for up to 48 weeks in patients with C9ORF72 ALS/FTD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacokinetics of TPN-101 as measured by concentrations of TPN-101 in plasma and cerebrospinal fluid (CSF)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the pharmacodynamic effect of TPN-101 on neurodegeneration as measured by changes in the levels of CSF and blood neurofilament light (NfL)</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the clinical effect of TPN-101 as measured by changes in score on the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R)</measure>
    <time_frame>48 weeks</time_frame>
    <description>The ALSFRS-R measures speech, salivation, swallowing, handwriting, cutting food and handling utensils (with or without gastrostomy), dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing, stairs, and breathing. Scores range from 0 to 40, with higher scores indicating that more function is retained.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>TPN-101, 400 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TPN-101, 400 mg/day</intervention_name>
    <description>400 mg/day of study investigational drug TPN-101 once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).</description>
    <arm_group_label>TPN-101, 400 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily for 24 weeks (double-blind treatment) followed by 400 mg/day TPN-101 for 24 weeks (open-label treatment).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have documentation of a clinical genetic test demonstrating the presence of a&#xD;
             confirmed repeat expansion in the C9orf72 gene from a CLIA certified laboratory&#xD;
&#xD;
          -  Score ≥ 18 on the Mini-Mental State Exam (MMSE) at Screening&#xD;
&#xD;
          -  Have a reliable caregiver to accompany the patient to all study visits.&#xD;
&#xD;
          -  For patients with ALS (with or without FTD):&#xD;
&#xD;
               -  Diagnosis of ALS (probable, possible, laboratory-supported probable or definite)&#xD;
                  according to the World Federation of Neurology revised E1 Escorial criteria&#xD;
&#xD;
               -  Onset of weakness within 3 years prior to Screening&#xD;
&#xD;
               -  Slow vital capacity (SVC) ≥ 60% of predicted normal adjusted for sex, age, and&#xD;
                  height (from the sitting position)&#xD;
&#xD;
               -  ALS Functional Rating Scale-Revised (ALSFRS-R) ≥ 30 at Screening&#xD;
&#xD;
          -  For patients with FTD:&#xD;
&#xD;
               -  A gradual, progressive decline in behavior, language, or motor function&#xD;
                  consistent with C9ORF72 hexanucleotide expansion-related syndrome such as&#xD;
                  behavioral variant FTD, primary progressive vaphasia, or amnestic syndrome&#xD;
&#xD;
               -  CDR Dementia Staging Instrument plus National Alzheimer's Coordinating Center&#xD;
                  Behavior and Language Domains (CDR plus NACC FTLD) global score of 0.5-2.0 at&#xD;
                  Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of other significant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of significant brain abnormality, including, but not limited to, prior&#xD;
             hemorrhage or infarct, cerebral contusion, encephalomalacia, aneurysm, vascular&#xD;
             malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess&#xD;
             or brain tumor such as meningioma); symptoms or signs of elevated intracranial&#xD;
             pressure, e.g., symptoms or history of head injury or abnormal funduscopic exam. If&#xD;
             there is history or evidence on neurologic exam suggesting possible subdural hematoma&#xD;
             (SDH), patients should be fully evaluated, including magnetic resonance imaging (MRI)&#xD;
             if indicated, to exclude significant, new SDH&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jay Soto</last_name>
    <phone>310-261-5312</phone>
    <email>clinicaltrials@transposonrx.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>FTD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

